PC
ROIV icon

PointState Capital’s Roivant Sciences ROIV Stock Holding History

PointState Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,791,440
Closed -$27.1M – 71
2025
Q3 		$27.1M Sell
1,791,440
-635,123
-26% -$7.86M 0.4% 42
2025
Q2 		$27.3M Sell
2,426,563
-288,560
-11% -$3.13M 0.42% 43
2025
Q1 		$27.4M Sell
2,715,123
-582,326
-18% -$6.3M 0.4% 42
2024
Q4 		$39M Sell
3,297,449
-810,403
-20% -$9.58M 0.71% 35
2024
Q3 		$47.4M Sell
4,107,852
-376,846
-8% -$4.29M 0.86% 27
2024
Q2 		$47.4M Buy
4,484,698
+438,213
+11% +$4.8M 1.03% 34
2024
Q1 		$42.6M Buy
+4,046,485
New +$43.6M 0.73% 38

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PointState Capital's ROIV Position: Q4 2025 in Review

PointState Capital sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 1,791,440 shares — an estimated $27.1M sold.

PointState Capital first reported a position in ROIV in Q1 2024 and held it in 7 quarters. The position peaked at $47.4M in Q3 2024. 400 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

  • PointState Capital reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
  • PointState Capital sold 1,791,440 Roivant Sciences shares in Q4 2025, an estimated $27.1M.
  • PointState Capital first reported a position in Roivant Sciences in Q1 2024 and held it in 7 quarters.
  • PointState Capital's Roivant Sciences position peaked at $47.4M in Q3 2024.
  • 400 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on PointState Capital's 13F filing for Q4 2025, filed 17 Feb 2026.